#Shanghai #USA #Pulmonary Hypertension #Pulnovo Medical #PADN-HF-PH

Pulnovo Medical Makes Waves at ESC 2026

Pulnovo Medical has recently announced compelling results from the PADN-HF-PH study, which were shared during the prominent "Hot Line 6" session at the European Society of Cardiology (ESC) Congress in 2026. Simultaneously, these findings were published in the respected "New England Journal of Medicine" (NEJM).

A Major Milestone in Cardiology

The study, which involved 264 patients suffering from pulmonary hypertension related to left ventricular hypertrophy (PH-LHD), showed an impressive 51% reduction in clinical deterioration risk. Patients who underwent the Pulmonary Artery Denervation (PADN) system, in conjunction with standard guideline-directed medical therapy (GDMT), displayed marked benefits in their health outcomes. Overall, the PADN system demonstrated the potential to significantly enhance the management of patients with heart failure and associated pulmonary conditions.

The PADN-HF-PH study stands as a comprehensive, multicenter, randomized controlled trial, shedding light on how experimental therapies might redefine intervention strategies for heart failure management. The research was spearheaded by academic leaders from esteemed institutions including Professor Shao-Liang Chen from Nanjing First Hospital, Yaling Han from General Hospital of Northern Theater Command, and Gregg W. Stone from Mount Sinai Hospital.

Statistical Highlights of the Findings

The study observed several key results that underline the effectiveness of PADN. The Kaplan-Meier estimated two-year incidence of clinical worsening was 25.7% for the PADN plus GDMT group versus 51.5% for the GDMT-only group, establishing PADN's pivotal role.

• - Risk Reduction: The hazard ratio was a striking 0.49 (95% CI: 0.30-0.82, p=0.006), indicating a substantial decrease in clinical decline risk over the follow-up period.
• - Recurring Clinical Events: The annualized rate of first and recurrent clinical events was calculated at 36.3 per 100 patient-years in the PADN group against 56.3 in the GDMT group, a reduction of 35.5%.
• - Functional Benefits: Notably, patients receiving PADN achieved a 24.8 meter improvement in the 6-Minute Walk Distance (6MWD). This marked advance reduces the likelihood of patients experiencing a drop in walking ability by 63%.

Furthermore, notable enhancements in quality of life and biomarker metrics such as NT-proBNP further validate the therapeutic advantages of PADN.

Safety Profile

Crucially, the procedure was well-tolerated with minimal complications; only two patients in the PADN group and one in the GDMT group experienced hematomas at the puncture site, and no other major adverse events were reported. This positions PADN as a promising approach in cardiovascular interventions.

Future Implications

The outcomes from the PADN-HF-PH study signal a potential shift in clinical paradigms concerning pulmonary hypertension and heart failure treatment. With solid evidence backing its efficacy, Pulnovo aims to expand its clinical investigations, further illuminating therapy possibilities for various pulmonary hypertension subtypes.

Such advancements not only broaden the horizon for patient treatment but also underscore the necessity of continued innovation in the field of cardiovascular health.

As Pulnovo Medical seeks to enhance treatment solutions through its proprietary technology platform, these findings illustrate the vital role of research in shaping the way we address heart health on a global scale. For more details on their initiatives and structures, interested parties are encouraged to visit www.pulnovomed.com.